MediGene AG · LS:A40ESG
MediGene — Q1 2014 Earnings Presentation
14 slides from MediGene's earnings presentation, May 15, 2014
Slide 1: Analyst conference call: Results for the first 3 months of 2014
Analyst conference call Results for the first 3 months of 2014 15 May 2014 Peter Llewellyn-Davies, CFO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila
Slide 3: Activities since beginning of 2014 – Immunotherapies
Activities since beginning of 2014 – Immunotherapies Transforming acquisition & integration of Trianta Immunotherapies DC vaccines: Ongoing investigator-initiated trials US patent relating to the manufacturing of mature dendritic cells granted TCR-modified T cells Ongoing development of GMP-complian
Slide 4: Activities since beginning of 2014 – advanced product portfolio
Activities since beginning of 2014 – advanced product portfolio Veregen®: Increase of Veregen® revenue by 95% Market launch in Sweden, Czech Republic, Slovakia, Hungary and Poland Commercialisation agreement for UK and Ireland EndoTAG®-1: Preparation of global Phase III study together with leading p
Slide 5: Financial Report 3M 2013
medigene Financial Report 3M 2013
Slide 6: Financial overview for the first 3 months 2014
Financial overview for the first 3 months 2014 Increase in revenue Total revenue up by 86% to €2.4 m (Q1 2013: €1.3 m) Veregen® revenue increased by 95% to €1.3 m (Q1 2013: €680 k) Reduction of loss EBITDA-based loss reduced by 37% to €1,5 m (Q1 2013: €-2,3 m) Net loss reduced by 38% to €2,0 m (Q1 2
Slide 7: Increase in revenue
Increase in revenue In € m -18% 86% 95% Revenue (in € k) 3M 2013 3M 2014 Change Veregen® Royalties 558 423 -24% Product revenue (supply chain) 70 226 >200% Milestone payments 52 680 >200% Veregen® revenue 680 1,329 95% Other operating income 629 1,101 75% Total revenue 1,309 2,430 86% 7
Slide 8: Operating expenses within plan
Operating expenses within plan In € m 21% -9% R&D expenses: SG&A expenses: Decrease in due to lower costs Higher costs due to Trianta for preclinical and clinical acquisition studies Total operating expenses Ongoing preparation of planned Within plan clinical trial for EndoTAG®-1 in cooperation with
Slide 9: Reduction of loss
Reduction of loss In € m 37% 38% Improvement due to increase in total revenue and stable operating expenses Improvement of 38% on net result of period 9
Slide 10: Financial guidance 2014 confirmed
Financial guidance 2014 confirmed Improvement Actual 2013 Guidance 2014 2014 Double-digit Total revenue €7.6 m 20 - 30% percentage increase Veregen® €4.2 m €5 - 6 m > 20% EBITDA loss €8.3 m €4 - 6 m > 25% Total revenue consists mainly of Revenue Veregen® Reimbursement of development costs; gra
Slide 11: Outlook 2014 for immunotherapy platforms - building a franchise in hematology
Outlook 2014 for immunotherapy platforms - building a franchise in hematology DC vaccines: Continuation of investigator-initiated trials Initiation of a further clinical study in AML in 2014 Additional clinical study in another hematological malignancy in 2015 TCR-modified T cells Development of GMP
Slide 12: Outlook for partnered portfolio in 2014
Outlook for partnered portfolio in 2014 Veregen® Growth in in-market sales to continue in double-digit percent range Market launches and approvals in additional countries Market authorization applications for further 7 - 9 European countries EndoTAG®-1 Further preparation for start of phase III TNBC
Slide 13: Questions & Answers
medigene Questions & Answers
Slide 14: Medigene AG contact details
Medigene AG MediGene AG T +49 - 89 - 20 00 33 - 0 Lochhamer Straße 11 F +49 - 89 - 20 00 33 - 2920 82152 Planegg Planegg/Martinsried / Martinsried investor@medigene.com Germany www.medigene.com Listed on Frankfurt Stock Exchange (MDG1, (MDG, Prime PrimeStandard) Standard)